OM
STOK icon

Opaleye Management’s Stoke Therapeutics STOK Stock Holding History

Opaleye Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.8M Buy
700,000
+5,000
+0.7% +$164K 3% 10
2025
Q4 		$22.1M Buy
695,000
+12,983
+2% +$390K 2.91% 7
2025
Q3 		$16M Buy
682,017
+119,897
+21% +$2.05M 2.27% 11
2025
Q2 		$6.38M Buy
562,120
+262,120
+87% +$2.49M 1.29% 18
2025
Q1 		$2M Buy
300,000
+275,000
+1,100% +$2.56M 0.44% 33
2024
Q4 		$276K Buy
+25,000
New +$307K 0.05% 38

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Opaleye Management's STOK Position: Q1 2026 in Review

Opaleye Management increased its Stoke Therapeutics (STOK) stake by 0.72% in Q1 2026, buying an estimated $164K and bringing the position to 700,000 shares worth $22.8M. The position accounts for 3% of the portfolio, ranked #10.

Opaleye Management first reported a position in STOK in Q4 2024 and has held it in 6 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Opaleye Management held 700,000 shares of Stoke Therapeutics worth $22.8M as of Q1 2026.
  • Opaleye Management bought 5,000 Stoke Therapeutics shares in Q1 2026, an estimated $164K.
  • Stoke Therapeutics made up 3% of Opaleye Management's portfolio in Q1 2026, its #10 holding.
  • Opaleye Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Opaleye Management's 13F filing for Q1 2026, filed 15 May 2026.